Skip to main content

PSA recurrence of prostate cancer: Update 2006

Publication ,  Other
Freedland, SJ; Moul, JW; Ward, JF
Published in: Consultant
December 1, 2006

Prostaste-specific antigen (PSA) recurrence is the most common form of advanced prostate cancer. Salvage therapies may be effective even among some high-risk men, although long-term cancer control data are limited The natural history of PSA recurrence is long but variable. The postrecurrence PSA doubling time can identify men at high risk for progression and death. Early hormonal therapy, possibly via combined androgen blockade, may reduce the risk of prograssion and improve cancer-specific survival among men with high-risk recurrence. Men with low-risk recurrences likely receive minimal benefit from aggressive early hormonal therapy and may actually be harmed.

Duke Scholars

Published In

Consultant

ISSN

0010-7069

Publication Date

December 1, 2006

Volume

46

Issue

14

Start / End Page

1613 / 1624

Related Subject Headings

  • General & Internal Medicine
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Freedland, S. J., Moul, J. W., & Ward, J. F. (2006). PSA recurrence of prostate cancer: Update 2006. Consultant.
Freedland, S. J., J. W. Moul, and J. F. Ward. “PSA recurrence of prostate cancer: Update 2006.” Consultant, December 1, 2006.
Freedland SJ, Moul JW, Ward JF. PSA recurrence of prostate cancer: Update 2006. Vol. 46, Consultant. 2006. p. 1613–24.
Freedland, S. J., et al. “PSA recurrence of prostate cancer: Update 2006.” Consultant, vol. 46, no. 14, 1 Dec. 2006, pp. 1613–24.
Freedland SJ, Moul JW, Ward JF. PSA recurrence of prostate cancer: Update 2006. Consultant. 2006. p. 1613–1624.

Published In

Consultant

ISSN

0010-7069

Publication Date

December 1, 2006

Volume

46

Issue

14

Start / End Page

1613 / 1624

Related Subject Headings

  • General & Internal Medicine